X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PIRAMAL ENTERPRISES BIOCON LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 72.6 39.6 183.3% View Chart
P/BV x 6.8 3.3 207.4% View Chart
Dividend Yield % 0.2 0.7 24.6%  

Financials

 BIOCON LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PIRAMAL ENTERPRISES
Mar-17
BIOCON LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1622,095 55.5%   
Low Rs4831,025 47.1%   
Sales per share (Unadj.) Rs194.6492.8 39.5%  
Earnings per share (Unadj.) Rs34.472.6 47.4%  
Cash flow per share (Unadj.) Rs48.394.7 51.0%  
Dividends per share (Unadj.) Rs1.0021.00 4.8%  
Dividend yield (eoy) %0.11.3 9.0%  
Book value per share (Unadj.) Rs241.9862.5 28.0%  
Shares outstanding (eoy) m200.00172.56 115.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.2 133.5%   
Avg P/E ratio x23.921.5 111.1%  
P/CF ratio (eoy) x17.016.5 103.4%  
Price / Book Value ratio x3.41.8 187.9%  
Dividend payout %2.928.9 10.0%   
Avg Mkt Cap Rs m164,440269,194 61.1%   
No. of employees `0009.24.0 230.1%   
Total wages/salary Rs m7,47017,939 41.6%   
Avg. sales/employee Rs Th4,213.921,190.3 19.9%   
Avg. wages/employee Rs Th809.04,470.1 18.1%   
Avg. net profit/employee Rs Th745.23,120.0 23.9%   
INCOME DATA
Net Sales Rs m38,91185,037 45.8%  
Other income Rs m1,5712,338 67.2%   
Total revenues Rs m40,48287,374 46.3%   
Gross profit Rs m9,79534,991 28.0%  
Depreciation Rs m2,7723,817 72.6%   
Interest Rs m26020,310 1.3%   
Profit before tax Rs m8,33413,202 63.1%   
Minority Interest Rs m1631,699 9.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m1,6162,281 70.8%   
Profit after tax Rs m6,88112,520 55.0%  
Gross profit margin %25.241.1 61.2%  
Effective tax rate %19.417.3 112.2%   
Net profit margin %17.714.7 120.1%  
BALANCE SHEET DATA
Current assets Rs m40,47787,590 46.2%   
Current liabilities Rs m16,783185,578 9.0%   
Net working cap to sales %60.9-115.2 -52.8%  
Current ratio x2.40.5 511.0%  
Inventory Days Days6031 192.0%  
Debtors Days Days8348 174.2%  
Net fixed assets Rs m45,073108,523 41.5%   
Share capital Rs m1,000345 289.8%   
"Free" reserves Rs m47,377148,481 31.9%   
Net worth Rs m48,377148,826 32.5%   
Long term debt Rs m21,082144,957 14.5%   
Total assets Rs m93,942482,394 19.5%  
Interest coverage x33.11.7 2,003.2%   
Debt to equity ratio x0.41.0 44.7%  
Sales to assets ratio x0.40.2 235.0%   
Return on assets %7.66.8 111.7%  
Return on equity %14.28.4 169.1%  
Return on capital %12.612.0 105.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98815,001 86.6%   
Fx outflow Rs m7,8995,150 153.4%   
Net fx Rs m5,0899,851 51.7%   
CASH FLOW
From Operations Rs m6,400-100,393 -6.4%  
From Investments Rs m-4,985-24,202 20.6%  
From Financial Activity Rs m-1,775135,705 -1.3%  
Net Cashflow Rs m-47311,110 -4.3%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare BIOCON LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 17, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS